



idigh.ca

# IDIGH

Programme en maladies infectieuses et immunité en santé mondiale  
Infectious Diseases and Immunity in Global Health Program  
La recherche pour le bénéfice de la santé mondiale  
Improving Global Health Through Research

## Séminaires en infection et immunité Infection and Immunity Seminar Series

Centre universitaire  
de santé McGill  
Institut de recherche



McGill University  
Health Centre  
Research Institute

5 octobre / October 5 (12:00)

Local D02.1312 et en ligne / Room D02.1312 and online

Site Glen, Bloc E, EM3.3211  
1001 Boul Décarie  
Montréal, QC H4A 3J1  
514-934-1934 ext 76174  
contact@idigh.ca

[ircusm.ca/mism](http://ircusm.ca/mism)  
[rimuhc.ca/idigh](http://rimuhc.ca/idigh)



# Bertrand Routy MD, PhD

Associate professor of Hemato-Oncology, University of Montreal (CHUM)  
Scientific Director of the CHUM Microbiome Center  
University of Montreal Research Centre (CRCHUM)

## The revolution of the gut microbiome in oncology

Upon his recruitment to the CRCHUM in 2018 after completing his PhD with Pr. Laurence Zitvogel, Dr. Routy quickly established himself as the scientific director of the CHUM Microbiome Centre where he began his work to develop novel microbiome-based therapeutics in oncology. His work contributed to the discovery of the gut microbiome as a novel prognostic biomarker for immune checkpoint inhibitors (ICI) in various cancers. He characterized the deleterious impact of antibiotic-related gut dysbiosis on ICI outcomes, which led to pivotal changes in clinical oncology practice. Moreover, he demonstrated that modulation of the microbiome by fecal microbiota transplantation, probiotics, and prebiotic supplementation had the potential to circumvent ICI resistance. His team currently leads several microbiodcentered trials in oncology ranging from phase I to phase II trials, with the aim of decreasing primary ICI resistance.

S'inscrire / Registration: [idigh.ca/webinars/bertrand-routy](http://idigh.ca/webinars/bertrand-routy)